Description
EMB-01 is an experimental medication currently being studied in clinical trials for colorectal cancer (CRC). It is being investigated as a potential treatment for patients with unresectable or metastatic CRC, meaning the cancer cannot be completely removed with surgery or has spread to other parts of the body. The trials are evaluating EMB-01 when given together with standard chemotherapy regimens (like those containing 5-Fluorouracil, Irinotecan, Oxaliplatin, Leucovorin, or Trifluridine). The goal of these early-phase trials (Phase 1b) is primarily to assess the safety and tolerability of EMB-01 in combination with chemotherapy and to find the best dose for further testing. Preliminary signs of effectiveness are also being looked for. These trials are open-label, meaning both the researchers and the patients know which treatment is being given.
Mechanism of Action
EMB-01 is being studied in combination with chemotherapy for colorectal cancer. The specific way EMB-01 works (its mechanism of action) is not fully detailed in the available information, but it is designed to be used alongside existing chemotherapy drugs. The trials are evaluating its effects in patients whose cancer may have specific genetic changes (like EGFR or VEGF mutations), suggesting it might target pathways related to these mutations or the tumor's response to chemotherapy. The exact molecular target is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.